Literature DB >> 20526191

Lidocaine, carbamazepine, and imipramine have partially overlapping binding sites and additive inhibitory effect on neuronal Na+ channels.

Ya-Chin Yang1, Chen-Syuan Huang, Chung-Chin Kuo.   

Abstract

BACKGROUND: Despite the structural differences, local anesthetics, anticonvulsants, and tricyclic antidepressants exert similar use-dependent actions against voltage-gated Na channels, which may be contributory to pain control. The authors explore whether these drugs could doubly occupy the channel and exert synergic clinical effect.
METHODS: The authors performed electrophysiologic recordings and quantitative analyses in mutant and native neuronal Na channels to investigate molecular interactions between different drugs.
RESULTS: The authors demonstrate significant interactions between F1764 and W1716, two residues reported for local anesthetic binding, indicating uncertainties to conclude a common drug-binding site by mutation data. Therefore, the authors performed detailed functional studies in native neurons. Quantitative analyses of the inactivation curve shift argue against effective double occupancy of different drugs. For example, the shift of 20.9 +/- 1.3 mV in the simultaneous presence of 10 microm imipramine, 100 microm lidocaine, and 100 microm phenytoin is consistent with the one-site (21.5 mV) rather than the two-site (30.5-33.8 mV) or three-site (42.7 mV) predictions. However, there is a deviation from the recovery courses predicted by one site if lidocaine or imipramine coexists with anticonvulsants. Moreover, gating state dependence of macroscopic-binding rates markedly differs between imipramine and carbamazepine.
CONCLUSIONS: Carbamazepine, lidocaine, and imipramine bind to a common site with the common aromatic motif. External to the aromatic site, there is another weaker and less gating-dependent site for the tertiary amine chain in the latter two drugs. Concomitant clinical use of these drugs, thus, should have at most a simple additive but not a synergistic inhibitory action on Na currents.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20526191     DOI: 10.1097/ALN.0b013e3181dc1dd6

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  12 in total

1.  Sidedness of carbamazepine accessibility to voltage-gated sodium channels.

Authors:  Sooyeon Jo; Bruce P Bean
Journal:  Mol Pharmacol       Date:  2013-12-06       Impact factor: 4.436

2.  Reverse pharmacogenomics: carbamazepine normalizes activation and attenuates thermal hyperexcitability of sensory neurons due to Nav 1.7 mutation I234T.

Authors:  Yang Yang; Talia Adi; Philip R Effraim; Lubin Chen; Sulayman D Dib-Hajj; Stephen G Waxman
Journal:  Br J Pharmacol       Date:  2017-07-30       Impact factor: 8.739

Review 3.  Clinical pharmacology of analgesics assessed with human experimental pain models: bridging basic and clinical research.

Authors:  Bruno Georg Oertel; Jörn Lötsch
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

4.  The Novel Activity of Carbamazepine as an Activation Modulator Extends from NaV1.7 Mutations to the NaV1.8-S242T Mutant Channel from a Patient with Painful Diabetic Neuropathy.

Authors:  Chongyang Han; Andreas C Themistocleous; Mark Estacion; Fadia B Dib-Hajj; Iulia Blesneac; Lawrence Macala; Carl Fratter; David L Bennett; Stephen G Waxman; Sulayman D Dib-Hajj
Journal:  Mol Pharmacol       Date:  2018-08-22       Impact factor: 4.436

5.  Antidepressants inhibit Nav1.3, Nav1.7, and Nav1.8 neuronal voltage-gated sodium channels more potently than Nav1.2 and Nav1.6 channels expressed in Xenopus oocytes.

Authors:  Takafumi Horishita; Nobuyuki Yanagihara; Susumu Ueno; Dan Okura; Reiko Horishita; Tomoko Minami; Yuichi Ogata; Yuka Sudo; Yasuhito Uezono; Takeyoshi Sata; Takashi Kawasaki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-09-14       Impact factor: 3.000

6.  Lacosamide Inhibition of Nav1.7 Voltage-Gated Sodium Channels: Slow Binding to Fast-Inactivated States.

Authors:  Sooyeon Jo; Bruce P Bean
Journal:  Mol Pharmacol       Date:  2017-01-24       Impact factor: 4.436

7.  Differences in local anaesthetic and antiepileptic binding in the inactivated state of human sodium channel Nav1.4.

Authors:  Amanda Buyan; Aidan A Whitfield; Ben Corry
Journal:  Biophys J       Date:  2021-11-11       Impact factor: 4.033

Review 8.  Voltage-gated sodium channels: pharmaceutical targets via anticonvulsants to treat epileptic syndromes.

Authors:  Mena Abdelsayed; Stanislav Sokolov
Journal:  Channels (Austin)       Date:  2013-03-26       Impact factor: 2.581

9.  Clinical use of antidepressant therapy and associated cardiovascular risk.

Authors:  W Stephen Waring
Journal:  Drug Healthc Patient Saf       Date:  2012-08-17

10.  Trigeminal neuralgia: An overview from pathophysiology to pharmacological treatments.

Authors:  Eder Gambeta; Juliana G Chichorro; Gerald W. Zamponi
Journal:  Mol Pain       Date:  2020 Jan-Dec       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.